
Mark A. Fisher MD (He/Him)
Clinical Investigator at Tekton Research, Inc.
Join to view full profile
14000 N PortlandSuite 101Oklahoma City, OK 73134
Phone+1 405-594-7712
Fax+1 888-721-0170
Dr. Fisher is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Mark Fisher, MD, is a neurologist based in Oklahoma City, OK. He completed his medical degree at Lewis Katz School of Medicine at Temple University in 1987, followed by residencies in Internal Medicine and Neurology, and a fellowship in Vascular Neurology at UT Houston. Dr. Fisher was an Assistant Professor of Neurology at the University of Oklahoma College of Medicine from 1995 to 2001. For five years he was a traumatic brain injury consultant at OptumServe, Inc.. He has worked with the Lynn Health Science Institute and Tekton, Inc., as principal investigator or subinvestigator in clinical trials.
Education & Training
University of Texas Health Science Center at HoustonFellowship, Vascular Neurology, 1992 - 1993
Detroit Medical Center/Wayne State UniversityResidency, Neurology, 1992
Michael Reese Hospital and Medical CenterResidency, Internal Medicine, 1987 - 1989
Lewis Katz School of Medicine at Temple UniversityClass of 1987
Certifications & Licensure
OK State Medical License 1995 - 2026
TX State Medical License 1992 - 2002
MI State Medical License 1990 - 1994
Clinical Trials
- Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures Start of enrollment: 2008 Dec 02
- Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Start of enrollment: 2025 Mar 18
- Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis Start of enrollment: 2025 May 27
Professional Memberships
- Member
- Member
Other Languages
- Russian
Industry Relationships
- Clinical investigator, Tekton, Inc.2025 - Present
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









